Danish healthcare major Novo Nordisk has slashed prices for a second time in India on its blockbuster obesity drug Wegovy, besides dropping prices on its diabetes product Ozempic, as well, this time. The move comes a little over a week after a patent on semaglutide (the active ingredient in Ozempic and Wegovy) expired in markets including India.
From April 1, 2026, the price of the starting dose of Ozempic will be reduced by 36 percent and starting dose of Wegovy will be reduced by 48 percent in India, the company said.
Following semaglutide’s patent loss on March 20th, several Indian companies including Natco, Dr Reddy’s Laboratories, Glenmark, Sun Pharma and Torrent Pharma, to name a few, launched their generic versions of the product, independently or with partners – at prices between 50 to 80 percent less than the innovator price. The generic products came in various delivery systems including vials with dosage-fixed syringes, pre-filled pens and even an oral version.
Price cuts
The starting doses of Ozempic (0.25 mg) and Wegovy (0.25 mg) will now be available in India at an effective daily price of ₹202 or a weekly price of ₹1,415 inclusive of taxes, Novo said. Last November, the company had taken a 37 percent price cut on its starting dose of Wegovy. Both products, and the generic versions are prescription-only products.
On the latest price-cut, Vikrant Shrotriya, Novo Nordisk India’s Managing Director, said in a statement, “By revising the price of our innovative treatments, we’re trying to make best-in-class cardiometabolic care more affordable for as many people with type 2 diabetes, overweight and obesity in India as possible. We’ve heard from patients and doctors, and we’re acting on that feedback. The burden of diabetes, obesity and related complications is immense for India, and we aim to bend this curve with effective, safe, and time-tested solutions.”